MedTrace Logo

Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma

NCT00422786 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2008-07-15

No results posted yet for this study

Summary

The purpose of this study was to evaluate the safety and efficacy of CAP-232 in the treatment of patients with previously treated (refractory) renal cell carcinoma

Conditions

  • Carcinoma, Renal Cell

Interventions

DRUG

CAP-232

Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period

Sponsors & Collaborators

  • Thallion Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Aline Guillot, MD · Institut de Cancérologie de la Loire, Dpt Oncologie Médicale, Saint-Priest en Jarez, France

  • Damien Pouessel, MD · CRLC Val d'Aurelle Paul-Lamarque, Montpellier, France

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00422786 on ClinicalTrials.gov